APP intracellular domain-WAVE1 pathway reduces amyloid-β production

Ilaria Ceglia; Christiane Reitz; Jodi Gresack; Jung Hyuck Ahn; Victor Bustos; Marina Bleck; Xiaozhu Zhang; Grant Martin; Sanford M. Simon; Angus C. Nairn; Paul Greengard; Yong Kim

doi:10.1038/nm.3924

APP intracellular domain-WAVE1 pathway reduces amyloid-β production

Ilaria Ceglia, Christiane Reitz, Jodi Gresack, Jung Hyuck Ahn, Victor Bustos, Marina Bleck, Xiaozhu Zhang, Grant Martin, Sanford M. Simon, Angus C. Nairn, Paul Greengard, Yong Kim

Department of Biochemistry

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

An increase in amyloid-β (Aβ) production is a major pathogenic mechanism associated with Alzheimer's disease (AD), but little is known about possible homeostatic control of the amyloidogenic pathway. Here we report that the amyloid precursor protein (APP) intracellular domain (AICD) downregulates Wiskott-Aldrich syndrome protein (WASP)-family verprolin homologous protein 1 (WAVE1 or WASF1) as part of a negative feedback mechanism to limit Aβ production. The AICD binds to the Wasf1 promoter, negatively regulates its transcription and downregulates Wasf1 mRNA and protein expression in Neuro 2a (N2a) cells. WAVE1 interacts and colocalizes with APP in the Golgi apparatus. Experimentally reducing WAVE1 in N2a cells decreased the budding of APP-containing vesicles and reduced cell-surface APP, thereby reducing the production of Aβ. WAVE1 downregulation was observed in mouse models of AD. Reduction of Wasf1 gene expression dramatically reduced Aβ levels and restored memory deficits in a mouse model of AD. A decrease in amounts of WASF1 mRNA was also observed in human AD brains, suggesting clinical relevance of the negative feedback circuit involved in homeostatic regulation of Aβ production.

Original language	English
Pages (from-to)	1054-1059
Number of pages	6
Journal	Nature Medicine
Volume	21
Issue number	9
DOIs	https://doi.org/10.1038/nm.3924
State	Published - 8 Sep 2015

Access to Document

10.1038/nm.3924

Cite this

@article{da80ded7af93435aa30265e72782d453,

title = "APP intracellular domain-WAVE1 pathway reduces amyloid-β production",

abstract = "An increase in amyloid-β (Aβ) production is a major pathogenic mechanism associated with Alzheimer's disease (AD), but little is known about possible homeostatic control of the amyloidogenic pathway. Here we report that the amyloid precursor protein (APP) intracellular domain (AICD) downregulates Wiskott-Aldrich syndrome protein (WASP)-family verprolin homologous protein 1 (WAVE1 or WASF1) as part of a negative feedback mechanism to limit Aβ production. The AICD binds to the Wasf1 promoter, negatively regulates its transcription and downregulates Wasf1 mRNA and protein expression in Neuro 2a (N2a) cells. WAVE1 interacts and colocalizes with APP in the Golgi apparatus. Experimentally reducing WAVE1 in N2a cells decreased the budding of APP-containing vesicles and reduced cell-surface APP, thereby reducing the production of Aβ. WAVE1 downregulation was observed in mouse models of AD. Reduction of Wasf1 gene expression dramatically reduced Aβ levels and restored memory deficits in a mouse model of AD. A decrease in amounts of WASF1 mRNA was also observed in human AD brains, suggesting clinical relevance of the negative feedback circuit involved in homeostatic regulation of Aβ production.",

author = "Ilaria Ceglia and Christiane Reitz and Jodi Gresack and Ahn, {Jung Hyuck} and Victor Bustos and Marina Bleck and Xiaozhu Zhang and Grant Martin and Simon, {Sanford M.} and Nairn, {Angus C.} and Paul Greengard and Yong Kim",

note = "Funding Information: This work was supported by the US National Institutes of Health (grants AG009464 (to P.G.) and AG047270 (to A.C.N.)), the Fisher Center for Alzheimer{\textquoteright}s Research Foundation (to P.G.) and the US Department of Defense–USAMRAA (grants W81XWH-09-1-0392 (to Y.K.) and W81XWH-09-1-0402 (to P.G.)). J.-H.A. was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (2010-0027945). We thank W. Luo for protocols for metabolic pulse labeling and chase and organelle fractionation; W.J. Netzer (The Rockefeller University, New York, New York, USA) for sAPPβ antibody and mNotch∆E plasmid; D. Cai for the budding-assay protocol; and S.S. Sisodia for the pCB6-APP695wt and pCB6-APP695swe plasmids. We also thank A. Schaeffer, P. Kurup, P. Lombroso, D. Tampellini, G. Gouras and R. Moir for discussion or sharing of materials. We acknowledge R. Norinsky and The Rockefeller University Transgenics Services Laboratory for their excellent in vitro fertilization services, Z. Dong for research assistance and E. Griggs for graphics. Publisher Copyright: {\textcopyright} 2015 Nature America, Inc. All rights reserved.",

year = "2015",

month = sep,

day = "8",

doi = "10.1038/nm.3924",

language = "English",

volume = "21",

pages = "1054--1059",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - APP intracellular domain-WAVE1 pathway reduces amyloid-β production

AU - Ceglia, Ilaria

AU - Reitz, Christiane

AU - Gresack, Jodi

AU - Ahn, Jung Hyuck

AU - Bustos, Victor

AU - Bleck, Marina

AU - Zhang, Xiaozhu

AU - Martin, Grant

AU - Simon, Sanford M.

AU - Nairn, Angus C.

AU - Greengard, Paul

AU - Kim, Yong

N1 - Funding Information: This work was supported by the US National Institutes of Health (grants AG009464 (to P.G.) and AG047270 (to A.C.N.)), the Fisher Center for Alzheimer’s Research Foundation (to P.G.) and the US Department of Defense–USAMRAA (grants W81XWH-09-1-0392 (to Y.K.) and W81XWH-09-1-0402 (to P.G.)). J.-H.A. was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (2010-0027945). We thank W. Luo for protocols for metabolic pulse labeling and chase and organelle fractionation; W.J. Netzer (The Rockefeller University, New York, New York, USA) for sAPPβ antibody and mNotch∆E plasmid; D. Cai for the budding-assay protocol; and S.S. Sisodia for the pCB6-APP695wt and pCB6-APP695swe plasmids. We also thank A. Schaeffer, P. Kurup, P. Lombroso, D. Tampellini, G. Gouras and R. Moir for discussion or sharing of materials. We acknowledge R. Norinsky and The Rockefeller University Transgenics Services Laboratory for their excellent in vitro fertilization services, Z. Dong for research assistance and E. Griggs for graphics. Publisher Copyright: © 2015 Nature America, Inc. All rights reserved.

PY - 2015/9/8

Y1 - 2015/9/8

N2 - An increase in amyloid-β (Aβ) production is a major pathogenic mechanism associated with Alzheimer's disease (AD), but little is known about possible homeostatic control of the amyloidogenic pathway. Here we report that the amyloid precursor protein (APP) intracellular domain (AICD) downregulates Wiskott-Aldrich syndrome protein (WASP)-family verprolin homologous protein 1 (WAVE1 or WASF1) as part of a negative feedback mechanism to limit Aβ production. The AICD binds to the Wasf1 promoter, negatively regulates its transcription and downregulates Wasf1 mRNA and protein expression in Neuro 2a (N2a) cells. WAVE1 interacts and colocalizes with APP in the Golgi apparatus. Experimentally reducing WAVE1 in N2a cells decreased the budding of APP-containing vesicles and reduced cell-surface APP, thereby reducing the production of Aβ. WAVE1 downregulation was observed in mouse models of AD. Reduction of Wasf1 gene expression dramatically reduced Aβ levels and restored memory deficits in a mouse model of AD. A decrease in amounts of WASF1 mRNA was also observed in human AD brains, suggesting clinical relevance of the negative feedback circuit involved in homeostatic regulation of Aβ production.

AB - An increase in amyloid-β (Aβ) production is a major pathogenic mechanism associated with Alzheimer's disease (AD), but little is known about possible homeostatic control of the amyloidogenic pathway. Here we report that the amyloid precursor protein (APP) intracellular domain (AICD) downregulates Wiskott-Aldrich syndrome protein (WASP)-family verprolin homologous protein 1 (WAVE1 or WASF1) as part of a negative feedback mechanism to limit Aβ production. The AICD binds to the Wasf1 promoter, negatively regulates its transcription and downregulates Wasf1 mRNA and protein expression in Neuro 2a (N2a) cells. WAVE1 interacts and colocalizes with APP in the Golgi apparatus. Experimentally reducing WAVE1 in N2a cells decreased the budding of APP-containing vesicles and reduced cell-surface APP, thereby reducing the production of Aβ. WAVE1 downregulation was observed in mouse models of AD. Reduction of Wasf1 gene expression dramatically reduced Aβ levels and restored memory deficits in a mouse model of AD. A decrease in amounts of WASF1 mRNA was also observed in human AD brains, suggesting clinical relevance of the negative feedback circuit involved in homeostatic regulation of Aβ production.

UR - http://www.scopus.com/inward/record.url?scp=84941022788&partnerID=8YFLogxK

U2 - 10.1038/nm.3924

DO - 10.1038/nm.3924

M3 - Article

C2 - 26280122

AN - SCOPUS:84941022788

SN - 1078-8956

VL - 21

SP - 1054

EP - 1059

JO - Nature Medicine

JF - Nature Medicine

IS - 9

ER -

APP intracellular domain-WAVE1 pathway reduces amyloid-β production

Abstract

Access to Document

Fingerprint

Cite this